الفهرس 
AbstractOnly 14 pages are availabe for public view
 |  | from | 242 |  |  |
| | | from | 242 | | |
Abstract
The present study was intended to formulate fast dissolving tablets (FDTs) of torsemide to enhance its bioavailability. 3:1 solid dispersions of torsemide and sorbitol or polyvinylpyrrolidone (PVP) k25 were prepared. The prepared SD was evaluated for in-vitro dissolution and physicochemical properties. The dissolution enhanced SD of torsemide with sorbitol was selected for formulation and optimization of torsemide fast dissolving tablets (FDTs). By means of Box-Bhenken design, 15 formulations were designed and prepared using Crosscarmellose sodium and crospovidone at various concentrations. The prepared FDTs tablets were evaluated. In-vitro release study was conducted in phosphate buffer pH 7.4 at 37ᵒC±0.5°C. Response surface methodology was used to study the effect of independent variables on response variables. The powder blend of F7 showed good flowability, no interaction and good stability upon storage at 30°C/75% RH and 40°C/75% RH for 3 months. The bioavailability of the selected FDT formulations F7 and F10 was studied following administration to Albino New Zealand rabbits. Cmax and the area under the plasma concentration–time curve of torsemide (AUC0–12) after administration of F7 or F10 were significantly higher than those obtained after administration of the ordinary commercial Torseretic ® tablets